These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L. J Nucl Med; 2019 Sep; 60(9):1253-1258. PubMed ID: 30902875 [Abstract] [Full Text] [Related]
6. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013 [Abstract] [Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Feb; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
14. Can 68 Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy? Khanna Y, Chinni V, Gnanasambantham K, O'Sullivan R, Ballok ZE, Ryan A, Ramdave S, Sivaratnam D, Bowden P, Guerrieri M, Ranasinghe WKB, Frydenberg M. BJU Int; 2023 Sep; 132(3):321-328. PubMed ID: 37190993 [Abstract] [Full Text] [Related]
15. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. McCarthy M, Francis R, Tang C, Watts J, Campbell A. Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448 [Abstract] [Full Text] [Related]
16. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S. Eur J Nucl Med Mol Imaging; 2019 Jan 15; 46(1):11-19. PubMed ID: 29905907 [Abstract] [Full Text] [Related]
17. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M. Eur J Nucl Med Mol Imaging; 2019 Sep 15; 46(10):2169-2177. PubMed ID: 31254037 [Abstract] [Full Text] [Related]
20. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study. Lengana T, van de Wiele C, Lawal I, Maes A, Ebenhan T, Boshomane T, Zeevaart JR, Ankrah A, Mokgoro N, Vorster M, Sathekge M. Nucl Med Commun; 2018 Feb 15; 39(2):179-185. PubMed ID: 29257006 [Abstract] [Full Text] [Related] Page: [Next] [New Search]